Mayo Clinic | Strategic Alliance Partners

October 18, 2013

A meta-analysis of nearly 2000 patients has shown that physical activity may substantially reduce the risk of developing esophageal cancer, especially esophageal adenocarcinoma.

October 17, 2013

Multiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.

September 20, 2013

Minetta Liu, MD, breast cancer specialist, Mayo Clinic, Rochester, Minnesota, discusses the limitations of radiology in metastatic breast cancer treatment.

September 03, 2013

A multisite, randomized, double-blind trial evaluating the fatigue-ameliorating properties of American ginseng in cancer patients and recent survivors has found the herb to be helpful in reducing some aspects of CRF, with the benefit strongest among patients currently in treatment.

August 07, 2013

Current T staging for renal cell carcinoma does not capture the full picture of tumor volume, which data have shown to be more predictive of survival and recurrence in certain types of cancer.

August 01, 2013

The results of the first prospective multicenter trial of cryoablation in lung cancer show that this emerging treatment may be a safe, effective, and minimally invasive method of helping a specific group of patients with advanced disease.

July 23, 2013

Minetta Liu, MD, Breast Cancer Specialist, Mayo Clinic, Rochester, Minnesota, discusses the use of circulating tumor cells (CTCs) for prognosis and prediction in patients with breast cancer.

May 08, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the mechanism of action of ruxolitinib in chronic myeloid leukemia.

April 15, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, describes three phase II and phase III trials in myelofibrosis.

March 25, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the long-term experience from the COMFORT-I and COMFORT-II trials in myelofibrosis.

March 11, 2013

Working in the laboratory and the clinic, Shaji K. Kumar, MD, has made a discovery: that there aren't enough hours in a day.

March 07, 2013

Shaji K. Kumar, MD, is working to understand the genomic intricacies of multiple myeloma, particularly the role played by activity associated with the TP53 gene.

February 28, 2013

Ruben A. Mesa, MD, Professor of Medicine, Division of Hematology & Medical Oncology, Mayo Clinic, discusses the use of JAK2 inhibitors in patients with myelofibrosis.

February 22, 2013

Axel Grothey, MD, from the Mayo Clinic in Rochester, Minnesota, discusses the effectiveness of bevacizumab beyond disease progression in metastatic colorectal cancer.

February 21, 2013

Genetic or drug-induced alterations of the enzyme CYP2D6 that result in reduced metabolism of tamoxifen are associated with a higher risk of recurrence and death in women with ER–positive breast cancer who receive the drug.

February 13, 2013

Edith A. Perez, MD, from the Mayo Clinic Cancer Center, discusses the antibody-drug conjugate T-DM1 that is being investigated as a treatment for patients with HER2-positive, unresectable, locally advanced or metastatic breast cancer.

February 07, 2013

Axel Grothey, MD, from the Mayo Clinic, Rochester, Minnesota, discusses a survey that examined the perceived benefits and use of adjuvant oxaliplatin in colon cancer.

February 01, 2013

Discussion with Edith Perez, MD, about key research presented at SABCS, ongoing developments in breast cancer treatment, and the current focal areas of her research.

January 30, 2013

The oral diabetic medication metformin may help improve survival in patients with ovarian cancer, according to the results of a retrospective case-control study.

November 06, 2012

Aleksandar Sekulic, MD, PhD, from the Mayo Clinic, Scottsdale, AZ, discusses the administration of vismodegib for the treatment and prevention of basal-cell carcinoma in patients with basal-cell nevus syndrome.